|[February 10, 2014]
Genocea Biosciences, Inc. Announces Closing of Initial Public Offering
CAMBRIDGE, Mass. --(Business Wire)--
Genocea Biosciences, Inc. today announced the closing of its initial
public offering of 5,500,000 shares of its common stock at a public
offering price of $12.00 per share. After underwriting discounts and
commissions and estimated offering expenses, Genocea received net
proceeds of approximately $61.4 million, excluding estimated offering
expenses. The shares are listed on the NASDAQ Global Market under the
ticker symbol "GNCA."
Citigroup and Cowen and Company are acting as joint book-running
managers for the offering. Stifel is acting as lead manager and Needham
& Company, LLC is acting as co-manager.
A registration statement relating to the securities being sold in this
offering was declared effective by the Securities and Exchange
Commission on February 4, 2014. This press release shall not onstitute
an offer to sell or a solicitation of an offer to buy and there shall
not be any sale of these securities in any state or jurisdiction in
which such an offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or jurisdiction.
A copy of the final prospectus related to these securities may be
obtained from Citigroup c/o Broadridge Financial Solutions, 1155 Long
Island Ave., Edgewood, NY 11717, by calling (800) 831-9146, or by
or Cowen and Company c/o Broadridge Financial Services, Attention:
Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by
calling (631) 274-2806, or by fax (631) 254-7140.
About Genocea Biosciences, Inc.
Genocea is harnessing the power of T cell immunity to develop the next
generation of vaccines. T cells are increasingly recognized as a
critical element of protective immune responses to a wide range of
infectious disease pathogens, but are difficult to target using
traditional vaccine discovery methods. Genocea is able to identify
protective T cell antigens in humans exposed to a pathogen using ATLAS™,
its proprietary technology platform, potentially enabling vaccines
against pathogens for which vaccine solutions do not exist or are
sub-optimal. Genocea's pipeline of novel T cell vaccines includes
GEN-003 for HSV-2 therapy, GEN-004, and earlier-stage programs in
chlamydia, HSV-2 prophylaxis and malaria.
[ Back To TMCnet.com's Homepage ]